Outlook Therapeutics Inc

NASDAQ:OTLKUnited States

Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing ONS-5010 (LYTENAVA (bevacizumab-vikg)), an ophthalmic formulation of bevacizumab for use in retinal indications. The Company's product candidate, ONS-5010, is developed to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab is a full-length, humanized anti-Vascular Endothelial Growth Factor (VEGF) recombinant monoclonal antibody (mAb), that inhibits VEGF and associated angiogenic activity. VEGF is a protein that promotes the growth of new abnormal blood vessels. Its biologics license application (BLA) for ONS-5010 in wet AMD involved three clinical trials, which include NORSE ONE, NORSE TWO and NORSE THREE. The Company sells ONS-5010 in the United States, United Kingdom, Europe, Japan and other markets.

Contact Information

Headquarters

111 S. Wood Avenue, Unit #100ISELIN, NJ, United States 08830

Phone

609-619-3990

Fax

---

Executives

Independent Executive Chairman of the Board

Ralph Thurman

President, Chief Executive Officer, Director

C. Russell Trenary

Chief Financial Officer, Executive Vice President, Treasurer, Company Secretary, Director

Lawrence Kenyon

Senior Vice President - Head of Europe

Jedd Comiskey

Senior Vice President - Licensing and M&A

Joel Prieve